LSAMP CHD1 Genomic Rearrangements Prostate Cancer Biomarkers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and treating prostate cancer in African descent populations are inadequate due to racial disparities in genetic biomarkers, with existing biomarkers being less effective in identifying aggressive forms of the disease and guiding treatment options.
Innovation Solution
The development of methods to detect genomic rearrangements such as LSAMP and CHD1 gene deletions in biological samples, which can identify aggressive prostate cancer and guide treatment decisions, particularly for African descent individuals, by using oligonucleotide probes and targeted therapies like PARP inhibitors and platinum-based agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If existing biomarkers (ERG, PCA3) are used for diagnosis, then diagnostic simplicity is maintained, but measurement precision and reliability are reduced in African descent populations
Solution Approach 1:
The patent segments the diagnostic approach by identifying specific genomic rearrangements (TMPRSS2:ERG, TMPRSS2:ETV4, TMPRSS2:ETV1 fusions and PTEN deletions) that can be detected through targeted molecular methods. This segmentation allows for more precise racial-specific biomarker detection while maintaining manageable diagnostic complexity through focused assay design.
Solution Approach 2:
The patent applies local quality by developing race-specific biomarker panels tailored to African descent populations. Rather than using a universal biomarker approach, the invention customizes the diagnostic markers (specific fusion genes and deletions) to match the genetic characteristics of different racial groups, thereby improving measurement precision for each population.
2Reliability
If genomic rearrangement detection methods are implemented, then measurement precision and reliability are improved, but ease of operation and device complexity increase
Solution Approach 1:
The patent applies preliminary action by pre-identifying and validating specific genomic rearrangements as biomarkers before clinical implementation. The research phase has already established the reliability of these markers in African descent populations, so clinicians can directly apply these pre-validated tests without needing to perform complex genomic analysis themselves, thus maintaining ease of operation while ensuring diagnostic reliability.
3Adaptability or versatility
If race-specific biomarkers are developed, then adaptability to different populations is improved, but loss of information about universal biomarkers occurs
Solution Approach 1:
The patent applies universality by creating a multi-functional diagnostic framework that includes both race-specific biomarkers (for population-tailored precision) and universal biomarkers (for broad applicability). The comprehensive panel can be adapted to different racial groups while maintaining a core set of universally relevant markers, thus preventing loss of universal information while gaining racial adaptability.
Data Source
AI summary
The present disclosure provides methods of identifying or characterizing prostate cancer comprising detecting in a biological sample the presence or absence of a genomic rearrangement that results in a deletion of an LSAMP gene and detecting in a biological sample the presence or absence of a genomic rearrangement that results in a deletion of a CHD1 gene. In certain embodiments, the patient self-identifies as being of African descent. Also disclosed herein are methods of testing for the presence of genomic rearrangements in an LSAMP gene and a CHD1 gene in a biological sample. The LSAMP and CHD1 genomic rearrangements serves as a biomarker for prostate cancer and can be used to stratify prostate cancer based on ethnicity or the severity or aggressiveness of prostate cancer and/or identify a patient for prostate cancer treatment. Also provided are kits for diagnosing and prognosing prostate cancer and methods of selecting a targeted prostate cancer treatment for a patient.